CA2在肝癌预后中的临床价值及相关分子机制研究

碳酸酐酶II（Carbonic Anhydrase II, CA2）是一种含锌金属酶，其表达和功能的异常与癌症预后密切相关，但CA2在肝癌预后中的临床价值，以及分子调控机制仍不清楚。我们前期肝癌组织分泌蛋白质组学和肝癌患者术后随访的血清蛋白质组学研究工作发现，CA2特异的被肝癌组织分泌，且肝癌病人的血清CA2浓度显著高于正常人群；更有价值的是当根治手术后的肝癌病人发生复发时，血清CA2浓度显著上升。因此，本项目拟系统分析CA2作为肝癌预后标志物的特异性、灵敏性和准确性，深入研究CA2的表达以及分泌对肝癌细胞的增殖、侵袭和迁移等生物学功能的影响，以及相应的分子机制。本项目的开展，能为肝癌的预后判断和干预提供潜在的新靶点。

Carbonic Anhydrase II (CA2) is a zinc metal enzyme, and the abnormal of its expression and functions is closely associated with cancer prognosis. While, the clinical significance of CA2 in hepatocellular carcinoma (HCC) prognosis and related molecular mechanisms are still unclear. In our preliminary HCC tissue secretome and follow-up serum peoteome studies, CA2 has been identified to be specifically secreted by HCC tissue, and the CA2 serum concentration in HCC patients was significantly higher than that in normal populations. Moreover, the serum CA2 concentration was significantly increased when the patients underwent recurrence after radical hepatectomy. Based on these prelimilary studies, this project attempts to further study the sensitivity, specificity and accuracy of CA2 on HCC prognosis, and the CA2 expression and secretion on the bioligical functions of HCC such as cell proliferation, invasion and metastasis, as well as its related molecular mechanisms . This project would provide us better understanding of HCC recurrence and metastasis, and potential novel targets for HCC diagnosis, prognosis and treatment.